Overview of safety of non-biologic and biologic DMARDs

• Published in: Rheumatology (Oxford, England) Vol. 51; no. suppl 6; pp. vi37 - vi43
• Main Author: Ruderman, E. M.
• Format: Journal Article
• Language: English
• Published: England 01.12.2012
• Subjects: Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Biological Products - adverse effects; Biological Products - therapeutic use; Clinical trials; Humans; Mycobacterium; Opportunistic Infections - epidemiology; Registries; Risk Factors; Treatment Outcome

Safety data come from a number of sources. Randomized clinical trials tend to be relatively short, exclude patients with significant comorbidity, have limited numbers of subjects and are primarily powered for efficacy. The most useful post-marketing data come from large national registries, such as...